The document discusses concerns about drug promotion and its impact on the rational use of medicines. It notes that less than half of countries effectively regulate drug promotion and most rely on industry self-regulation. The document also provides several examples of misleading or unsubstantiated drug advertising from different countries. It concludes that public health and welfare should come before industry interests and that patients need unbiased information on treatment options instead of disguised advertising.